Format

Send to

Choose Destination
See comment in PubMed Commons below
Antimicrob Agents Chemother. 2014 May;58(5):2979-81. doi: 10.1128/AAC.00037-14. Epub 2014 Mar 3.

Cross-resistance between clofazimine and bedaquiline through upregulation of MmpL5 in Mycobacterium tuberculosis.

Author information

1
Ecole Polytechnique Fédérale de Lausanne, Global Health Institute, Lausanne, Switzerland.

Abstract

The antileprosy drug clofazimine is also of interest for the treatment of multidrug-resistant tuberculosis. To understand possible resistance mechanisms, clofazimine-resistant Mycobacterium tuberculosis mutants were isolated in vitro, and, unexpectedly, found to be cross-resistant to bedaquiline. Mutations in the transcriptional regulator Rv0678, with concomitant upregulation of the multisubstrate efflux pump, MmpL5, accounted for this cross-resistance. Mutation in Rv0678 should therefore be considered a confounding factor for the treatment of tuberculosis with clofazimine or bedaquiline.

PMID:
24590481
PMCID:
PMC3993252
DOI:
10.1128/AAC.00037-14
[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for PubMed Central
    Loading ...
    Support Center